America Great Health (AAGH)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
America Great Health (AAGH) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 56/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026America Great Health (AAGH) Gesundheitswesen & Pipeline-Uebersicht
America Great Health, a biotechnology company established in 2013, focuses on the research and development of protein and peptide small molecular drugs, alongside manufacturing AI cloud computing-based diagnostic devices, cell therapies, and regenerative medicine, positioning itself within the competitive healthcare sector.
Investmentthese
America Great Health presents a high-risk, high-reward investment opportunity within the biotechnology sector. Key value drivers include the successful development and commercialization of its protein and peptide small molecular drugs, as well as the adoption of its AI cloud computing-based diagnostic devices. The company's focus on cell therapy and regenerative medicine also offers long-term growth potential. However, the company's negative profit margin of -173.0% and high beta of 6.35 indicate significant financial risks. The absence of a dividend further reduces its attractiveness to income-seeking investors. Upcoming catalysts include potential breakthroughs in its drug development pipeline and partnerships for its AI-based diagnostic devices. Investors should carefully consider the company's financial stability and the competitive landscape before investing.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- America Great Health operates with a small team of 5 employees, indicating a lean operational structure.
- The company's negative P/E ratio of -4.26 reflects its current lack of profitability.
- AAGH's profit margin of -173.0% highlights significant financial challenges and operational inefficiencies.
- The company boasts a high gross margin of 91.1%, suggesting strong pricing power on its existing products.
- AAGH's high beta of 6.35 indicates substantial volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Focus on innovative technologies like AI and cell therapy.
- High gross margin of 91.1% indicates strong pricing power.
- Potential for breakthrough discoveries in drug development.
- Established presence in the health and wellness supplement market.
Schwaechen
- Negative profit margin of -173.0% indicates financial instability.
- Small team of 5 employees limits operational capacity.
- Limited financial resources for research and development.
- High beta of 6.35 indicates significant market volatility.
Katalysatoren
- Upcoming: Potential breakthroughs in the development of protein and peptide small molecular drugs.
- Upcoming: Successful clinical trials and regulatory approvals for new drugs and devices.
- Ongoing: Expansion of AI-based diagnostic devices in the healthcare sector.
- Ongoing: Strategic partnerships and collaborations with larger companies.
- Ongoing: Growth in the cell therapy and regenerative medicine market.
Risiken
- Potential: Intense competition in the biotechnology and pharmaceutical industries.
- Potential: Regulatory hurdles and lengthy approval processes for new drugs and devices.
- Potential: Patent expiration and generic competition.
- Ongoing: Negative profit margin of -173.0% indicates financial instability.
- Ongoing: Limited financial resources for research and development.
Wachstumschancen
- Expansion of AI-Based Diagnostic Devices: The market for AI in healthcare diagnostics is projected to reach $6.7 billion by 2026, offering a significant growth opportunity for America Great Health. By leveraging its AI cloud computing-based diagnostic devices, the company can tap into this growing market. Successful development and commercialization of these devices could drive revenue growth and improve profitability. Timeline: Ongoing.
- Development of Protein and Peptide Small Molecular Drugs: The global market for peptide therapeutics is expected to reach $41.8 billion by 2028. America Great Health's focus on researching and developing protein and peptide small molecular drugs positions it to capitalize on this growing market. Successful clinical trials and regulatory approvals could lead to significant revenue streams. Timeline: Ongoing.
- Cell Therapy and Regenerative Medicine: The regenerative medicine market is projected to reach $53.6 billion by 2025. America Great Health's involvement in cell therapy and regenerative medicine offers long-term growth potential. Advances in these fields could lead to breakthrough treatments for various diseases and conditions. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers can accelerate the development and commercialization of America Great Health's products. Collaborations can provide access to funding, expertise, and distribution channels. Timeline: Ongoing.
- Expansion into International Markets: Expanding into international markets, particularly in Asia and Europe, can broaden America Great Health's customer base and revenue streams. Adapting its products and services to meet the needs of different markets can drive growth. Timeline: Ongoing.
Chancen
- Expansion of AI-based diagnostic devices in the healthcare sector.
- Development and commercialization of protein and peptide small molecular drugs.
- Growth in the cell therapy and regenerative medicine market.
- Strategic partnerships and collaborations with larger companies.
Risiken
- Intense competition in the biotechnology and pharmaceutical industries.
- Regulatory hurdles and lengthy approval processes for new drugs and devices.
- Patent expiration and generic competition.
- Economic downturns and reduced healthcare spending.
Wettbewerbsvorteile
- Proprietary AI cloud computing-based diagnostic technology.
- Intellectual property related to protein and peptide small molecular drugs.
- Expertise in cell therapy and regenerative medicine.
- Established brand reputation in the health and wellness supplement market.
Ueber AAGH
America Great Health, founded in 2013 and headquartered in Alhambra, California, operates as a biotechnology company focused on the research, development, and manufacturing of innovative healthcare solutions. Originally known as Crown Marketing, the company transitioned to America Great Health in March 2017, signaling a strategic shift towards biotechnology. The company's core activities include the research and development of protein and peptide small molecular drugs, targeting various therapeutic areas. Additionally, America Great Health manufactures and sells AI cloud computing-based diagnostic and medical devices, leveraging artificial intelligence to enhance diagnostic accuracy and efficiency. The company is also involved in cell therapy and regenerative medicine, exploring advanced treatments for various diseases and conditions. Furthermore, America Great Health offers a range of supplements, catering to the growing demand for health and wellness products. With a small team of 5 employees, the company focuses on innovation and technological advancement within the biotechnology sector.
Was das Unternehmen tut
- Researches and develops protein and peptide small molecular drugs.
- Manufactures and sells AI cloud computing-based diagnostic and medical devices.
- Engages in cell therapy research and development.
- Develops regenerative medicine technologies.
- Offers a range of health and wellness supplements.
- Leverages AI to enhance diagnostic accuracy and efficiency.
Geschaeftsmodell
- Generates revenue through the sale of AI cloud computing-based diagnostic and medical devices.
- Seeks to generate revenue through the sale of protein and peptide small molecular drugs upon successful development and regulatory approval.
- Aims to generate revenue from cell therapy and regenerative medicine products and services.
- Generates revenue through the sale of supplements.
Branchenkontext
America Great Health operates within the dynamic and competitive biotechnology industry, characterized by rapid innovation and evolving market trends. The industry is driven by advancements in genomics, proteomics, and personalized medicine. The market for AI-based diagnostic devices is experiencing significant growth, fueled by the increasing adoption of artificial intelligence in healthcare. Competitors like ADXS, AGNPF, AGTX, APLIF, and HESG are also vying for market share in the biotechnology and pharmaceutical sectors. America Great Health's success depends on its ability to differentiate itself through innovative products and strategic partnerships.
Wichtige Kunden
- Hospitals and clinics utilizing AI-based diagnostic devices.
- Research institutions involved in drug development and clinical trials.
- Patients seeking cell therapy and regenerative medicine treatments.
- Consumers purchasing health and wellness supplements.
Finanzdaten
Chart & Info
America Great Health (AAGH) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer AAGH verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer AAGH.
Kursziele
Wall-Street-Kurszielanalyse fuer AAGH.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von AAGH auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Mike Qingkun Wang
CEO
Mike Qingkun Wang is the CEO of America Great Health, leading a team of 5 employees. His background includes experience in managing small teams and guiding the strategic direction of the company. He has overseen the company's transition from Crown Marketing to America Great Health, focusing on biotechnology and healthcare solutions. His leadership is crucial in driving the company's research and development efforts and commercialization strategies.
Erfolgsbilanz: Under Mike Qingkun Wang's leadership, America Great Health has focused on developing AI cloud computing-based diagnostic devices and exploring cell therapy and regenerative medicine. He has guided the company's efforts in researching and developing protein and peptide small molecular drugs. His strategic decisions have shaped the company's direction in the biotechnology sector.
AAGH OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that America Great Health may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- Low trading volume and liquidity.
- High volatility and price swings.
- Risk of delisting or suspension from the OTC market.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been in operation since 2013.
- Focus on research and development in the biotechnology sector.
- Development of AI cloud computing-based diagnostic devices.
- Headquartered in Alhambra, California.
America Great Health Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for AAGH?
America Great Health (AAGH) currently holds an AI score of 56/100, indicating moderate score. Key strength: Focus on innovative technologies like AI and cell therapy.. Primary risk to monitor: Potential: Intense competition in the biotechnology and pharmaceutical industries.. This is not financial advice.
How frequently does AAGH data refresh on this page?
AAGH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AAGH's recent stock price performance?
Recent price movement in America Great Health (AAGH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on innovative technologies like AI and cell therapy.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AAGH overvalued or undervalued right now?
Determining whether America Great Health (AAGH) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AAGH?
Before investing in America Great Health (AAGH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AAGH to a portfolio?
Potential reasons to consider America Great Health (AAGH) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Focus on innovative technologies like AI and cell therapy.. Additionally: High gross margin of 91.1% indicates strong pricing power.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of AAGH?
Yes, most major brokerages offer fractional shares of America Great Health (AAGH) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track AAGH's earnings and financial reports?
America Great Health (AAGH) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for AAGH earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- OTC data may be limited or unreliable.
- Financial data based on available information and may not be comprehensive.
- AI analysis pending.